Company registration number 03244013 (England and Wales)
HEALTH EDGE SOLUTIONS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
HEALTH EDGE SOLUTIONS LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 11
HEALTH EDGE SOLUTIONS LIMITED
BALANCE SHEET
AS AT 31 AUGUST 2025
31 August 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
1,221,914
1,265,717
Tangible assets
5
224,350
178,611
1,446,264
1,444,328
Current assets
Stocks
512,331
363,569
Debtors
6
1,316,749
1,029,259
Cash at bank and in hand
1,657,000
2,114,299
3,486,080
3,507,127
Creditors: amounts falling due within one year
7
(2,536,580)
(2,576,854)
Net current assets
949,500
930,273
Total assets less current liabilities
2,395,764
2,374,601
Provisions for liabilities
(74,484)
(104,277)
Net assets
2,321,280
2,270,324
Capital and reserves
Called up share capital
8
200
200
Revaluation reserve
42,930
44,297
Profit and loss reserves
2,278,150
2,225,827
Total equity
2,321,280
2,270,324

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

HEALTH EDGE SOLUTIONS LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 AUGUST 2025
31 August 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 21 May 2026 and are signed on its behalf by:
Mr P A J Player
Director
Company Registration No. 03244013
HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
- 3 -
1
Accounting policies
Company information

Health Edge Solutions Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 16 Northavon Business Centre, Dean Road, Yate, Bristol, BS37 5NH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development Costs
15 years
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings Leasehold
2% straight line
Fixtures and fittings
15% - 25% reducing balance
Computer equipment
33.3% straight line
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 5 -
1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

 

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 6 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
1
Accounting policies
(Continued)
- 7 -
1.15
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
18
17
HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 8 -
4
Intangible fixed assets
Development Costs
£
Cost
At 1 September 2024
2,028,316
Additions
97,948
At 31 August 2025
2,126,264
Amortisation and impairment
At 1 September 2024
762,599
Amortisation charged for the year
141,751
At 31 August 2025
904,350
Carrying amount
At 31 August 2025
1,221,914
At 31 August 2024
1,265,717
5
Tangible fixed assets
Land and buildings Leasehold
Fixtures and fittings
Computer equipment
Motor vehicles
Total
£
£
£
£
£
Cost or valuation
At 1 September 2024
213,237
212,404
99,530
29,300
554,471
Additions
-
0
101,621
14,389
-
0
116,010
At 31 August 2025
213,237
314,025
113,919
29,300
670,481
Depreciation and impairment
At 1 September 2024
77,087
177,379
92,154
29,240
375,860
Depreciation charged in the year
4,200
56,383
9,628
60
70,271
At 31 August 2025
81,287
233,762
101,782
29,300
446,131
Carrying amount
At 31 August 2025
131,950
80,263
12,137
-
0
224,350
At 31 August 2024
136,150
35,025
7,376
60
178,611
HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
5
Tangible fixed assets
(Continued)
- 9 -

During 2008 the freehold property was revalued to £210,000.

If revalued assets were stated on an historical cost basis rather than a fair value basis, the total amounts

included would have been as follows:

2025
2024
£
£
Cost
141,667
141,667
Accumulated depreciation
(52,647)
(49,814)
Carrying value
89,020
91,853
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
865,166
572,466
Other debtors
451,583
456,793
1,316,749
1,029,259
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
420,013
310,087
Taxation and social security
699,279
275,353
Other creditors
1,417,288
1,991,414
2,536,580
2,576,854
HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 10 -
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of £1 each
100
100
100
100
Ordinary B shares of £1 each
100
100
100
100
200
200
200
200

The 'A' and 'B' shares rank pari passu save for the following:

 

1) The holders of the 'B' shares shall not be entitled by reason of their holding such shares to receive notice of, attend or vote at any General Meeting of the company.

 

2) Where a dividend is declared in respect of both classes of shares the company may, by ordinary resolution, differentiate between the classes as to the amount and percentage of dividend payable, but in default the shares in each such class shall be deemed to rank pari passu in all respects as if they constituted one class of shares.

 

3) On winding up or other repayment of capital, the assets of the company (including capital uncalled at the commencement of the winding up) remaining after paying and discharging the debts and liabilities of the company and the costs of winding up shall be applied in the following order of priority: i) in repayment of the capital paid up or credited as paid up on the 'A' shares (including any premium) and ii) in repayment of the capital paid up or credited as paid up on the 'B' shares (including any premium): and the residue (if any) shall be divided amongst the holders of the 'B' shares in proportion to the nominal amount paid up or credited as paid up on such shares.

9
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
41,083
87,323
HEALTH EDGE SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 11 -
10
Related party transactions

During the year, the company traded on commercial terms with the following companies in which three of the directors, P Player, A Thomas and D Fitzgerald are directors. These are as follows:-

 

Health Edge Consumables Limited

Star Office Management Limited

Transactions with related parties

During the year the company entered into the following transactions with related parties:

Name of related party
Nature of relationship
Other related parties
Common directors
Description of transaction
Income
Payments
2025
2024
2025
2024
£
£
£
£
Purchases
-
0
-
0
1,257,104
1,203,163
Management recharges/services
-
0
-
0
713,976
785,625
Sales
294,611
259,065
-
0
-
0
Amounts owed to/by related parties

The following amounts were outstanding at the reporting end date:

Amount owed to
Amounts owed by
2025
2024
2025
2024
£
£
£
£
Other related parties
-
0
101,363
271,179
251,980
11
Directors' transactions

 

 

Description
% Rate
Opening balance
Interest charged
Amounts repaid
Closing balance
£
£
£
£
Mr A R Thomas - 1-3
2.25
46,000
1,322
(1,322)
46,000
Mr A R Thomas - 4
-
108,283
-
-
108,283
Mr P A J Player - 1
2.25
6,997
201
(201)
6,997
161,280
1,523
(1,523)
161,280
2025-08-312024-09-01falsefalsefalse21 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr A R ThomasMrs S J ThomasMr M FordMs D A FitzgeraldMr T T HoareMr P A J PlayerMrs S J Thomas032440132024-09-012025-08-31032440132025-08-31032440132024-08-3103244013core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-08-3103244013core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-08-3103244013core:LandBuildingscore:LongLeaseholdAssets2025-08-3103244013core:FurnitureFittings2025-08-3103244013core:ComputerEquipment2025-08-3103244013core:MotorVehicles2025-08-3103244013core:LandBuildings2024-08-3103244013core:FurnitureFittings2024-08-3103244013core:ComputerEquipment2024-08-3103244013core:MotorVehicles2024-08-3103244013core:CurrentFinancialInstrumentscore:WithinOneYear2025-08-3103244013core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3103244013core:CurrentFinancialInstruments2025-08-3103244013core:CurrentFinancialInstruments2024-08-3103244013core:ShareCapital2025-08-3103244013core:ShareCapital2024-08-3103244013core:RevaluationReserve2025-08-3103244013core:RevaluationReserve2024-08-3103244013core:RetainedEarningsAccumulatedLosses2025-08-3103244013core:RetainedEarningsAccumulatedLosses2024-08-3103244013core:ShareCapitalOrdinaryShareClass12025-08-3103244013core:ShareCapitalOrdinaryShareClass12024-08-3103244013core:ShareCapitalOrdinaryShareClass22025-08-3103244013core:ShareCapitalOrdinaryShareClass22024-08-3103244013core:ShareCapitalOrdinaryShares2025-08-3103244013core:ShareCapitalOrdinaryShares2024-08-3103244013bus:Director52024-09-012025-08-3103244013core:IntangibleAssetsOtherThanGoodwill2024-09-012025-08-3103244013core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-09-012025-08-3103244013core:LandBuildingscore:LongLeaseholdAssets2024-09-012025-08-3103244013core:FurnitureFittings2024-09-012025-08-3103244013core:ComputerEquipment2024-09-012025-08-3103244013core:MotorVehicles2024-09-012025-08-31032440132023-09-012024-08-3103244013core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-08-3103244013core:DevelopmentCostsCapitalisedDevelopmentExpenditurecore:ExternallyAcquiredIntangibleAssets2024-09-012025-08-3103244013core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-08-3103244013core:FurnitureFittings2024-08-3103244013core:ComputerEquipment2024-08-3103244013core:MotorVehicles2024-08-31032440132024-08-3103244013core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-08-3103244013core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-09-012025-08-3103244013bus:OrdinaryShareClass12024-09-012025-08-3103244013bus:OrdinaryShareClass22024-09-012025-08-3103244013bus:OrdinaryShareClass12025-08-3103244013bus:OrdinaryShareClass12024-08-3103244013bus:OrdinaryShareClass22025-08-3103244013bus:OrdinaryShareClass22024-08-3103244013bus:AllOrdinaryShares2025-08-3103244013bus:AllOrdinaryShares2024-08-3103244013core:ExpensesReimbursed2024-09-012025-08-3103244013core:ManagementRechargesServices2024-09-012025-08-3103244013core:SaleOrPurchaseGoods2024-09-012025-08-3103244013core:ExpensesReimbursed2023-09-012024-08-3103244013core:ManagementRechargesServices2023-09-012024-08-3103244013core:SaleOrPurchaseGoods2023-09-012024-08-3103244013bus:PrivateLimitedCompanyLtd2024-09-012025-08-3103244013bus:SmallCompaniesRegimeForAccounts2024-09-012025-08-3103244013bus:FRS1022024-09-012025-08-3103244013bus:AuditExemptWithAccountantsReport2024-09-012025-08-3103244013bus:Director12024-09-012025-08-3103244013bus:Director22024-09-012025-08-3103244013bus:Director32024-09-012025-08-3103244013bus:Director42024-09-012025-08-3103244013bus:Director62024-09-012025-08-3103244013bus:CompanySecretary12024-09-012025-08-3103244013bus:FullAccounts2024-09-012025-08-31xbrli:purexbrli:sharesiso4217:GBP